Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investors.urogen.com
Leave the platform to read the original full article on the publisher site.
Source: UroGen Pharma
Scope: Industry
Related coverage
More related coverage
BioInvent International AB publishes Annual Report 2025
Sobi publishes Annual and Sustainability Report for 2025
Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for...
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen
De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibilite...
Our R&D Approach
Powered by innovation, our R&D teams are driven to generate advances in drug discovery, out-innovate...